This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Severe. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
When these two medicines are taken together, you may experience an increased chance for kidney problems caused by one or both medicines.
What might happen:
Your kidney may not work as well.
What you should do about this interaction:
Make sure that your doctor knows all of the medicines that you are taking.Contact your healthcare professionals (e.g. doctor or pharmacist) as soon as possible about taking these two medicines together. Your doctor may want to stop your ataluren temporarily while you are taking the aminoglycoside antibiotic.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Translarna (ataluren) EU SPC. PTC Therapeutics International Limited July 31, 2014.
- 2.Gentamicin Sulfate in 0.
- 3% Sodium Chloride Injection. Baxter Healthcare Corporation June 2011.
- 4.Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995 Mar;39(3):650-5.
- 5.Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999 Jul;43(7):1549-55.
- 6.Gerlach AT, Stawicki SP, Cook CH, Murphy C. Risk factors for aminoglycoside-associated nephrotoxicity in surgical intensive care unit patients. Int J Crit Illn Inj Sci 2011 Jan;1(1):17-21.
- 7.Kerem E, Konstan MW, De Boeck K, et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med 2014 Jul;2(7):539-47.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.